Unilever is one of the world’s leading consumer goods companies. At present, it is manufacturing and selling around 400 brands in more than 190 countries. Recently, another concern of the organization, Unilever Overseas Holdings BV has become the new proprietor of GSK Bangladesh Ltd. In other words, the giant MNC purchased 82% shares of GlaxoSmithKline (GSK) pharmaceuticals.
Read more: Facebook Shares Dropped Down 8.3% Due to Advertiser Strike
On the other hand, GSK Bangladesh is a subordinate of a leading British pharmaceutical GlaxoSmithKline plc. From the start, it officially came into the record of the Dhaka Stock Exchange in 1976. On December 3, 2018, Unilever NV pronounced that it would purchase GSK shares.
The GSK headquarters later in 2018 went into an agreement with another European global Unilever to sell health food and beverage businesses around the world.
As per Dhaka Stock Exchange (DSE), Unilever bought 98.75 lakh shares from Setfirst Ltd through the block market. In other words, Setfirst is a sister concern of GSK.
Read more: Fair & Lovely to Lose Fair From Its Name
Consequently, Unilever bought each share of GSK at Tk2,046.3 and the total transaction value stood at Tk2,020.75 crore. To emphasize, it is so far the highest trade value of an individual company in the history of DSE.
In the meantime, GSK covered its 60-year-old pharmaceuticals business in Bangladesh in 2018. Be that as it may, as a pharmaceuticals unit, it was confronting misfortunes. Therefore, to halt further misfortunes, the GSK board chose to cut down the blinds on the business.
In effect of closing down the pharmaceuticals business, it made a benefit of Tk98.57 crore in the last financial year. Additionally, it prescribed a 530 percent dividend to its investors.
At this instant, the sponsors and executives hold 81.98% of the total share. Alongside them, institutional investors hold 15.53%. Among the rest of the shares, foreign investors hold 0.37% and the local investors hold 2.12% portions of the company.
The Current Business Operation of GSK Bangladesh
Following the worldwide arrangement, the two gatherings in India have merged their concerned companies.
However, in Bangladesh, they favored a mother organization of Unilever to purchase out lion’s share portions of GSK Bangladesh from the Headquarter.
At the present time, Horlicks adds to around 93 percent of GSK Bangladesh’s yearly deals. The rest originates from primarily Sensodyne toothpaste. However, there are some minor items like over the antacid brand Eno.
In the meantime, in the main quarter of the current monetary year, the overall gain of the organization has expanded by 35.44 percent to Tk18.04 crore. During the period, its profit per share was Tk14.97. Hence, the settled up capital of GSK is now Tk12.04 crore.
